Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$74.51 USD

74.51
1,186,610

-0.27 (-0.36%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $74.49 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (152 out of 248)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on stronger base volume recovery and growth from strategic acquisitions.

Reasons to Add West Pharmaceutical (WST) to Your Portfolio Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Hologic (HOLX) closed at $78.96 in the latest trading session, marking a -1.69% move from the prior day.

Boston Scientific (BSX) Gets FDA Nod for Vercise Software

by Zacks Equity Research

Boston Scientific's (BSX) Vercise Neural Navigator 5 Software has an improved user interface that presents patient data in an easier-to-understand style and enables better therapy delivery.

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on strategic acquisitions and robust performance of the DSA and RMS arms.

Is AmerisourceBergen (ABC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how AmerisourceBergen (ABC) and Hologic (HOLX) have performed compared to their sector so far this year.

Hyperfine (HYPR) ACTION PMR Study Targets Better Stroke Care

by Zacks Equity Research

Hyperfine's (HYPR) ACTION PMR study focuses on utilizing point-of-care brain imaging to identify strokes and salvageable brain tissue.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

New product developments and the pending NuVasive acquisition raise optimism about the Globus Medical (GMED) stock.

Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Thermo Fisher (TMO) Launches Diomni Enterprise Software

by Zacks Equity Research

Thermo Fisher's (TMO) Diomni Enterprise Software effortlessly connects each individual processing stage to a single, integrated platform.

Glaukos (GKOS) Stock Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

DexCom (DXCM) Stock Hits 52-Week High: More Room to Grow?

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

CVS Health (CVS) Launches Caremark Cost Saver With a New Pact

by Zacks Equity Research

CVS Health (CVS) is able to dynamically shop for the lowest price on its clients' behalf with the help of Caremark Cost Saver solution.

3 Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors remain optimistic about QIAGEN (QGEN) backed by the performance of the NGS portfolio and diagnostic solutions.

Illumina's (ILMN) Latest Launch to Boost Genomics Analysis

by Zacks Equity Research

Illumina's (ILMN) DRAGEN v4.2 is expected to improve the identification of genetic disease causes, drug discovery and population genomics.

Alcon (ALC) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are bullish about Alcon (ALC) owing to solid demand, strong commercial execution and pricing improvements across the Surgical and Vision Care franchises.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Stryker (SYK) Launches Q Guidance System for Cranial Surgeries

by Zacks Equity Research

Stryker (SYK) launches its Q Guidance system with Cranial Guidance software, offering surgeons a comprehensive planning and guidance solution for complex cranial procedures.

Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Hologic (HOLX) closed at $79.10 in the latest trading session, marking a +0.7% move from the prior day.

DaVita (DVA) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about DaVita's (DVA) strength in its kidney care.

Integra's (IART) Codman EVD Catheter Study Data Favorable

by Zacks Equity Research

Integra's (IART) Codman Bactiseal EVD lowers financial burdens and guarantees a safe clinical outcome in patients with aSAH-related hydrocephalus.

Here's Why You Should Add McKesson (MCK) to Your Portfolio

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Alcon (ALC) Surgical End Market Grows, Vision Care Sales Rise

by Zacks Equity Research

In Equipment, Alcon (ALC) continues to upgrade and expand its installed base with the CENTURION and LEGION devices.